Spotlight of the month: Unified Patent Court captures 15% of European patent litigation but still far from being primary European patent court
Changes to the proposed new medicinal products Directive have been approved by the EU Parliament – do they shift the balance between generics and innovators and are they TRIPS compliant?
Mathys & Squire files Petition for Review for Ipsen Bioinnovation
Mathys & Squire recognised as one of Europe’s leading patent firms in the Financial Times 2024 rankings
Fifteen Mathys & Squire attorneys recognised in IAM Patent 1000 2024
Sign up to Mathys Matters, our monthly newsletter, to receive all the latest insights, expert analysis, and key updates on intellectual property and sector developments, delivered directly to your inbox.